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Many human diseases with a high disease burden worldwide such as for example different forms 
of cancer, infectious diseases and autoimmune diseases are affected by the polysaccharide Heparan 
Sulfate (HS). The actions of HS largely depend on the structure of its polysaccharide chains that 
provide specific binding sites for proteins.  
The aim of this master project was to gain more understanding of how the biosynthesis of HS is 
regulated, focusing on the HS biosynthesis enzymes, exostosin (EXT)1 and EXT2. The EXT-
proteins have a key role in generating the HS polysaccharide backbone composed of alternating 
glucuronic acid (GlcA) and N-acetylglucosamine (GlcNAc) units. It is suggested that the 
biologically functional unit in HS chain elongation is a Golgi-complex containing EXT1 and 
EXT2. Due to the low enzyme activities of EXT2 it has been speculated that EXT2 is not involved 
in the actual elongation of the HS backbone but serves as a transport protein to transport EXT1 
from the endoplasmic reticulum to the Golgi apparatus where HS elongation takes place. This will 
mean that EXT1 alone is elongating HS. Still, there are some indications that EXT2 may have 
some, but low, elongating enzyme activity. However, this has been difficult to study as the EXT 
proteins tend to associate with each other and to remain associated also after purification. In this 
thesis, to be able to in detail study of individual enzyme activities of the EXT proteins, human cells 
lacking either EXT1 or EXT2 were transiently transfected with the full-length EXT2 plasmid and 
EXT1plasmid DNA in EXT1 and EXT2 deficient cells, respectively.   
In this study we found that when the EXT2 protein was expressed in mouse cells lacking EXT1, 
the expressed EXT2 transferred glucuronic acid to an acceptor oligosaccharide, indication that 
EXT2 has HS elongating activity. However, this result was not repeated when similar experiments 
were done in a human cell line lacking EXT1. Further studies are needed to determine the role of 
EXT2 on HS elongation.  
  




ABSTRACT ........................................................................................................................................... i 
ABBREVIATIONS ............................................................................................................................. iv 
ACKNOWLEDGEMENTS ................................................................................................................ vi 
1 INTRODUCTION ....................................................................................................................... 1 
 Proteoglycans and glycosaminoglycans ................................................................................. 1 
 Heparan sulfate/heparin proteoglycans .................................................................................. 3 
 HSPGs associated with the cell surface ....................................................................................... 3 
 HSPGs found in the ECM ............................................................................................................ 4 
 HSPGs found inside the cells ....................................................................................................... 4 
 Functions of heparan sulfate proteoglycans ........................................................................... 5 
 Biosynthesis of heparan sulfate .............................................................................................. 7 
 HS chain initiation and elongation ......................................................................................... 7 
 HS chain initiation ....................................................................................................................... 7 
 HS chain elongation/polymerization ............................................................................................ 8 
 HS chain modifications ................................................................................................................ 8 
 THE EXT-FAMILY ............................................................................................................. 10 
 EXT1 and EXT2 ..........................................................................................................................10 
 EXTL1 .........................................................................................................................................11 
 EXTL2 .........................................................................................................................................11 
 EXTL3 .........................................................................................................................................12 
 Exostosin proteins and hereditary multiple exostoses .......................................................... 12 
2 AIMS/OBJECTIVES ................................................................................................................ 13 
3 RELEVANCE TO GLOBAL HEALTH ................................................................................. 14 
4 MATERIALS ............................................................................................................................. 15 
5 METHODS ................................................................................................................................. 19 
 Cell culture ........................................................................................................................... 19 
 Cell splitting ......................................................................................................................... 19 
 Cell Freezing ........................................................................................................................ 19 
 Cell transfection ................................................................................................................... 20 
 Protein expression analysis................................................................................................... 20 
 Glycosyltransferase assays ................................................................................................... 20 
 Western blot analysis. ........................................................................................................... 21 
 BCA protein assay ......................................................................................................................21 
 SDS PAGE electrophoresis .........................................................................................................22 
 Gel Chromatography ............................................................................................................ 23 
 Gel column preparation ..............................................................................................................23 
iii | P a g e  
 
 Sephadex G-25 gel chromatography ...........................................................................................23 
 Gene expression analysis by RT-PCR .................................................................................. 24 
 RNA extraction ............................................................................................................................24 
 cDNA synthesis ...........................................................................................................................24 
 Quantitative real Time-Polymerase chain reaction (RT-PCR) ...................................................24 
 Immunofluorescence staining ............................................................................................... 25 
 Cell plate preparation .................................................................................................................25 
 Cell staining ................................................................................................................................25 
 Metabolic labeling with 3H-glucosamine and analysis of heparan sulfate structure ............ 26 
 3H-glucosamine metabolic labeling ............................................................................................26 
 Alkali treatment to release O-linked oligo and polysaccharides from proteins ..........................26 
 Isolate free chains on DEAE-Sephacel .......................................................................................26 
 Desalting using PD 10 Columns .................................................................................................27 
 Chondroitinase ABC digestion....................................................................................................27 
 Superose 6 HPLC gel filtration column ......................................................................................28 
6 RESULTS ................................................................................................................................... 29 
 EXT1 deficient (EXT1KO) B16F10 mouse melanoma cells transfected with tGFP tagged EXT2 
plasmid DNA ................................................................................................................................... 29 
 Protein expression analysis by Western blotting. .......................................................................29 
 EXT2 mRNA expression levels in WT control, EXT1KO control, WT+ EXT2 and EXT1KO+EXT2 
B16F10 mouse melanoma cells ...................................................................................................................30 
 Glycosyltransferase activity in WT control, EXT1KO control and EXT1KO+EXT2 B16F10 mouse 
melanoma cells ............................................................................................................................................31 
 Immunofluorescence staining .....................................................................................................33 
 EXT1 deficient MV3 human cells transfected with tGFP tagged EXT2 plasmid DNA ...... 33 
 Protein expression analysis by Western blotting ........................................................................34 
 EXT2 mRNA expression levels in WT control, EXT1KO control, WT+ EXT2 and EXT1 KO+EXT2 
MV3 human cells .........................................................................................................................................35 
 Glycosyltransferase activity in WT control, EXT1KO control and EXT1 KO+EXT2 MV3 human cells
 36 
 EXT2 deficient B16F10 mouse melanoma transfected with full-length human C-terminal myc-
DDK-tagged EXT1 plasmid DNA ................................................................................................... 36 
 Protein expression analysis by Western blotting. .......................................................................36 
 EXT1 mRNA expression levels in WT control, EXT2KO control, WT+ EXT1 and EXT2KO+EXT1 
B16F10 mouse melanoma cells. ..................................................................................................................37 
 Glycosyltransferase activity in WT control, EXT2KO control and EXT2 KO+EXT1 B16F10 mouse 
melanoma cells ............................................................................................................................................38 
7 DISCUSSION ............................................................................................................................. 39 
8 CONCLUSION .......................................................................................................................... 42 
9 REFERENCES .......................................................................................................................... 43 
 
iv | P a g e  
 
ABBREVIATIONS 
HS  Heparan sulfate 
CS  Chondroitin sulfate 
PG  Proteoglycan 
HSPG  Heparan sulfate proteoglycan 
CSPG  Chondroitin sulfate proteoglycan 
GAGs  Glycosaminoglycans 
ECM  Extracellular matrix 
EXT  Exostosin 
EXTL  Exostosin like 
EXT1KO Exostosin 1 Knock-out 
EXT2KO Exostosin 2 Knock-out 
WT  Wild Type 
MO  Multiple osteochondromas 
NDST  N-deacetylase/N-sulfotransferase 
DMEM Dulbecco’s modified Eagle’s medium 
RPMI  Roswell Park Memorial Institute 
PBS  Phosphate buffered saline 
RT-PCR Real time polymerase chain reaction 
RNA  Ribonucleic acid 
DNA  Deoxyribonucleic acid 
cDNA  Complementary Deoxyribonucleic acid 
HPRT  Hypoxanthine-guanine phosphoribosyltransferase 
POLR2F Polymerase II Subunit F 
SDS  Sodium dodecyl sulfate 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HRP  Horse radish peroxidase 
ECL  Enhanced chemiluminescence 
IgG  Immunoglobulin G 
GlcA  Glucuronic acid  
GlcNAc N-acetylglucosamine  
v | P a g e  
 
UDP  Uridine diphosphate 
Myc  myc tag, a polypeptide protein tag derived from the c-myc gene product 
tGFP  turbo bright green fluorescent protein 
DEAE  Diethylaminoethyl  
PFA  Paraformaldehyde 



































First and foremost, all praises and gratitude to the Almighty, for His sprinkles of blessings 
throughout my research work to complete the research successfully during the Covid-19 pandemic.  
 
I would like to express my wholehearted gratitude to my research supervisor, Prof. Marion Kusche-
Gullberg, Department of Biomedicine, University of Bergen, Norway, for giving me the 
opportunity to conduct this research and providing inestimable guidance throughout the research. 
Her perseverance, vision, sincerity and motivation have inspired me. It was a tremendous privilege 
and honor to be a part of this research under her supervision.  I am grateful to her for her continuous 
support in lab work and edifying lectures regarding the research project throughout the research. 
She has invested lots of her valuable time and always kept encouraging me till the last of my thesis. 
I am grateful to her for the enormous support to make me understand every step of the research and 
lab work. I have got a precious opportunity to work with her which has created a strong platform 
for me. I am extremely grateful to her for her friendly, empathetic and encouraging behavior 
throughout the research process that has helped me to complete the research.  
 
I would like to thank Mona Helen Grønning for her immense technical support in the lab. I am 
extremely grateful to her because of her efforts what she has dedicated for me to complete all the 
lab works without making mistakes as much as possible. She has been assisting me as a shadow of 
mine while conducting experiments in the lab. Accomplishing my thesis would be very 
cumbersome without her assistance.  
I would also like to extend my thanks to Prof. Donald Gullberg for his valuable guidance during 
the laboratory sessions regarding my thesis that helped me to a lot utilizing the thesis ideas. I am 
also thankful to all members of Matrix Biology family for supporting me all the way through my 
research.  
I am very much grateful to my family members for their constant support, love and prayers to 
complete my thesis. 
 
Osman Goni. 
University of Bergen, Norway. 
May 2021. 
1 | P a g e  
 
1 INTRODUCTION  
 
Heparan sulfate (HS) is a sulfated polysaccharide that is bound to different proteins to form heparan 
sulfate proteoglycans (HSPGs). HSPGs are found at cell surfaces and in the extracellular matrix 
(ECM). HS is similar to the polysaccharide heparin but in contrast to heparin, that is only found 
inside mast cells but HS is made by all cells in the body. Heparin is used in the clinics as an 
anticoagulant since1935s (Rabenstein, 2002). However, the physiological role of heparin in the 
mammalian body is unclear but its function is probably related to storage of proteases in connective 
tissue mast cell granules (Mulloy et al., 2017). Heparin chains are uniformly sulfated whereas HS 
has a more varied structure, composed of sulfated and non-sulfated domains. HSPGs play 
important roles in several physiological and pathological processes, including normal fetal 
development, wound healing, inflammation, microbial infections and cancer progression. (Bishop 
et al., 2007)(Li & Kusche-Gullberg, 2016).  
 
The biological activities depend on the ability of HS to bind proteins in a selective fashion. Some 
mouse models with defects in enzymes involved in HS biosynthesis are embryonic lethal whereas 
others show different abnormalities including formation of bone tumors, abnormal skeletal and 
kidney development and eye defects. Mutations caused by disturbed HS synthesis in humans are 
mostly autosomal dominant inherited disorders, often with overlapping phenotypic features, 
characterized by growth disorders and skeletal deformities or are linked to neurologic disorders (Li 
& Kusche-Gullberg, 2016). There has been a lot of studies on the biosynthesis of HS and how the 
large structural variation of HS contributes its ability to bind other molecules and thus influence 
both physiological and pathological events. However, the regulation of HS biosynthetic machinery 
that generates cell specific HS structures, is still poorly understood. 
 Proteoglycans and glycosaminoglycans   
Proteoglycans (PGs) are glycoproteins composed of a core protein with one or more covalently 
attached polysaccharide chains called glycosaminoglycans (GAGs)(Li & Kusche-Gullberg, 2016) 
(Fig.1). 
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Fig. 1: Schematic figure of a proteoglycan molecule containing a core protein with attached glycosaminoglycan 
chains (Marie et al., 2011).  
 
GAGs are long unbranched polysaccharide chains consisting of a backbone of repeating 
disaccharide units composed of a hexuronic acid (glucuronic acid, GlcA or iduronic acid, IdoA) or 
a galactose (Gal) and a hexosamine (N-acetylglucosamine, GlcNAc or N-acetylgalactosamine, 
GalNAc) residues. Most GAG chains are sulfated to a variable extent, which allows a large degree 
of structural variation. Based on the nature and sulfation level of the repeated disaccharide, GAGs 
can be divided into several classes: heparan sulfate (HS), heparin (a highly sulfated variant of HS), 
chondroitin sulfate (CS), dermatan sulfate, keratan sulfate and hyaluronan (Kristian Prydz, 2015). 
The repeating disaccharide in HS and heparin is GlcA/IdoA-GlcNAc and in CS GlcA-GalNAc. 
Dermatan sulfate (GlcA/IdoA-GalNAc) is similar to CS but in dermatan sulfate some GlcA 
residues have been epimerized to IdoA. In keratan sulfate the hexuronic acid has been replaced by 
a galactose and keratan sulfate is built up of alternating galactose (Gal) and GlcNAc residues 
(Kusche-Gullberg & Kjellén, 2003). Hyaluronan is composed of repeating GlcA-GlcNAc 
disaccharide units and, in contrast to the other GAGs, it is not linked to a core protein and is not 
sulfated (Fig. 2).  When different types of GAG-chains are attached to the same core protein it is 
called a hybrid PG (Noborn et al., 2016). The sulfated polysaccharide chains are highly negatively 
charged molecules. The modification of GAG chains by sulfation at different site contribute to their 
ability to bind to and modulate the activity of a multitude of ligands thus influencing biological 
processes, from patterning and organogenesis in the early embryo to adult homeostasis and ageing 
(Kramer, 2010). This thesis will mostly deal with HS focusing on its biosynthesis, functions and 
the EXT proteins. 
 





Fig. 2: The structure and disaccharide composition of glycosaminoglycans (GAGs). The backbone of GAGs 
consists of repeating disaccharide subunits, composed of uronic acid or galactose and an amino sugar. Linkages are 
shown in red and sites of sulphation are indicated by yellow lightning bolts. GlcA, D-glucuronic acid; GlcNAc, N-
acetyl-D-glucosamine; GalNAc, N-acetyl-D-galactosamine; Gal, D-galactose; IdoA, L-iduronic acid. Figure from  
(Crijns et al., 2020).  
 
 
 Heparan sulfate/heparin proteoglycans  
Heparan sulfate proteoglycans (HSPGs) are major components of the ECM and ubiquitously 
present on the cell surface (Li & Kusche-Gullberg, 2016).  HSPGs can be classified after the sugar 
composition of their GAG chains as described above. However, it is more common to classify 
HSPGs according to their cellular localization: associated with the cell membrane, in the ECM or 
inside the cell.  
 HSPGs associated with the cell surface 
The two main families of cell surface HSPGs are syndecans and glypicans. The cell surface HSPGs 
can modulate a number of cellular events like cell-cell and cell-matrix interaction, cellular signaling 
and internationalization of ligands. Syndecans are transmembrane proteins containing HS or both 
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HS and CS chains. In humans, there are four syndecans: syndecan-1-4. Syndecan-2 and syndecan-
4 carry only HS chains whereas syndecan-1 and syndecan-3 can have both HS and CS chains.  
Glypicans are attached to the cell membrane by a glycosyl-phosphatidylinositol (GPI) anchor. The 
human glypican family has 6 members, glypican 1-6, that all have HS chains. Another 
characteristic for all glypicans is that the HS chains are located close to the plasma membrane (Hull 
et al., 2017)  
 
 HSPGs found in the ECM 
Perlecan, collagen XVIII, and agrin are HSPGs found in the basement membrane, a network of 
ECM proteins found on the basolateral membrane of epithelial and endothelial cells around other 
cell types, such as muscle, Schwann and fat cells. These PGs are connected to other ECM molecules 
such as for example, fibronectin and collagens. By acting as cross-linkers of different ECM 
components, they provide support for cells. They have many different functions in development 
and wound healing that depend on both the core proteins and the GAG chains.  
Perlecan is expressed by vascular smooth muscle cells and endothelial cells and released into the 
basement membrane (Annaval et al., 2020). Perlecan is a one of the largest monomeric matrix 
molecules. With GAG chains perlecan has a Mw of more than 750 kDa (the core protein is 
approximately 500 kDa and can be modified by the addition of 3-4 HS-chains and rarely one CS 
chain, approximately 65 kDa each) (Kallunki & Tryggvason, 1992)   
Agrin is also a large ECM PG that is widely expressed in basement membranes and is important 
for the development of the neuromuscular junctions during embryogenesis.  
Collagen XVIII has structural properties of both triple helical collagen and a HSPG. Proteolytic 
cleavage of the C-terminus of collagen type XVIII releases a domain called endostatin, that can 
reduce the vascular growth in tumors(Hull et al., 2017).    
 
 HSPGs found inside the cells 
Serglycin is the only known PG in this class. Serglycin is found in secretory granules of 
hematopoietic cells and carry heparin and/or CS chains. Serglycin got its name because of its 
characteristic, extensive region of Ser-Gly repeats in the core protein. In connective tissue mast 
cells, the GAG is heparin whereas in other hematopoietic cells serglycin carry CS chains. This PG 
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Fig. 3. This figure illustrates different HSPG according to location. Syndecan and glypican are present on the cell 
membrane, perlecan and agrin are found in the ECM and serglycin in mast cell granules. Figure from (Filipek-Górniok 
et al., 2021).  
 
 Functions of heparan sulfate proteoglycans  
HSPGs are involved in both physiological and pathological processes throughout embryonic 
development, adult live and ageing. HSPGs interact with myriad of different proteins, such as 
proteases and their inhibitors, growth factors and morphogens, chemokines and adhesion proteins 
and can therefore mediate and regulate various cellular events (Bishop et al., 2007)(Gallagher, 
2015) (Fig. 4). Depending on the molecules, the activity of the bound factors is either enhanced or 
inhibited by the binding to HS. The role of HSPGs in cell-signaling is an extensively studied field. 
HSPGs serve as co-receptors for growth factors and mediate their efficiency of binding to the 
receptor and causes activation of their high affinity receptors (Gallagher, 2015). Many signaling 
molecules such as for example fibroblast growth factors (FGFs), Wingless (Wnt/Wg), hedgehog 
(Hh), transforming growth factor-beta (TGF-beta) and bone morphogenic protein (BMP) need 
binding to HSPGs for proper function (Häcker et al., 2005). 
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Fig. 4: Different functions of HSPGs. Heparan sulfate proteoglycans (HSPGs) contribute to the formation of the 
glycocalyx at the cell surface and are ubiquitously present in the extracellular matrix, where they interact with a myriad 
of different HS binding proteins. In doing so, they integrate the flow of information that circulates in-between cells 
and upstream signaling that is mediated by the cytokines/growth factors-receptor interaction. They are also further 
involved in chemokines/morphogens gradient stabilization and presentation, cell migration and adhesion or microbial 
adsorption, thereby regulating many fundamental biological processes. Figure from (Annaval et al., 2020).  
 
Pathogens, like many viruses (including herpes simplex virus, zika virus, HIV-virus and Covid-19-
virus), parasites (like Trypanosoma cruzi), and bacteria (like leptospira, N. gonorrhoeae) bind to 
HS on the cell surface. This helps the pathogen to bind it’s cell suface protein receptor on the cell 
membrane and leads to internatization of the pathogen (Cagno et al., 2019)(Clausen et al., 2020).  
 
The biological activities of HS largely depend on the location of sulfate groups on the 
polysaccharide chain that provide binding sites for myriad of proteins. Also, the number and length 
of the HS chains control the biological activities of HS. Some molecules, like the plasma protease 
inhibitor antithrombin and FGF2, bind to specific sulfation patterns (Fig. 5B) (van den Born et al., 
1995)(Forsberg & Kjellén, 2001). Other molecules bind non-specifically to negative regions in HS. 
The structure of HSPG is cell and tissue-specific and change during development, with age and 
disease. More than one type of core protein can occur on the same cell type, but it is generally 
believed that the structure of the HS chain is cell specific. Consequently, HS chains from specific 
cell type have the same type of structure irrespective of core protein. Although both the core protein 
and the polysaccharide chain are important for the function of HSPGs, mutations in genes for 
various core proteins give generally (but not always) milder phenotypic change than lack of various 
enzymes that are involved in HS biosynthesis (Forsberg & Kjellén, 2001). This is most probably 
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due to that most cells synthesize several types of HSPGs and thus HS chains will still be present 
on the cells even when one species of core protein is missing.           
 Biosynthesis of heparan sulfate 
 
Like DNA, RNA and protein synthesis, the formation of HS structure is not template driven. 
Instead, it depends on the organization and substrate specificity of the enzymes (approx. 25 
different enzymes), the amount of precursor molecules (UDP-sugars and sulfate donor) and the 
rate of flow through the Golgi apparatus. The enzymes involved in HS synthesis are 
glycosyltransferases which build the HS backbone and modification enzymes, sulfotransferases 
and epimerases, that modify the sugars residues in patterns characteristic for each cell-type. The 
glycosyltransferases transfer activated sugars (UDP-sugars) to generate the HS polysaccharide 
backbone. The sulfate groups that will be incorporated into the growing chain by sulfotransferases 
must be activated before the sulfation reaction. In mammals, the activated form of the sulfate is the 
sulfonucleotide 3-phosphoadenosine 5-phosphosulfate (PAPS). The core proteins and enzymes 
involved in HS biosynthesis are formed in the rough endoplasmic reticulum (ER) and are 
transported to the Golgi compartment where HS chain formation occur (K. Prydz & Dalen, 2000) 
(Li & Kusche-Gullberg, 2016).  
 
 HS chain initiation and elongation 
 HS chain initiation 
HS and CS chain formation is initiated by the formation of a tetrasaccharide called the GAG-protein 
linkage region. It is formed by addition of xylose to a serin residue in a serin-glycine sequence in 
the core protein by xylosyltransferase (Xyl) 1 or 2. Then two galactose residues are added by 
galactosyltransferase (GalT)-I and II, respectively. Finally, the last sugar in the HS- and CS-protein 
linkage region, a GlcA, is added by glucuronyltransferase (GlcAT) -I. During biosynthesis of both 
HS and CS the GAG-linker tetrasaccharide is modified by phosphorylation of the xylose residue 
which is necessary for elongation by stimulating galactosyltransferase II activity (Wen et al., 2014). 
The two galactose residues can be sulfated but this has only been observed for CSPG linker regions 
(de Waard et al., 1992). Addition of a fifth sugar unit determines if CS or HS chains will be 
synthesized on the core protein. Addition of a GalNAc residue results in synthesis of CS/dermatan 
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sulfate, while the transfer of a GlcNAc unit to the tetrasaccharide linkage region initiates HS 
synthesis (Li & Kusche-Gullberg, 2016).  
 
 
 HS chain elongation/polymerization 
Elongation of HS chain is initiated by the addition of a GlcNAc unit to the linker region by 
exostosin-like 3. Then an enzyme complex of exostosin proteins EXT1 and EXT2 elongates HS 
chains by the alternating addition of GlcA and GlcNAc residues (Busse et al., 2007). The “stop 
signal” for chain elongation is not known and HS chains typically contain between 50–200 
disaccharides. 
 
 HS chain modifications 
During HS elongation HS chains are modified in a sequential process involving: 1) partial N-
deacetylation/N-sulfation of GlcNAc units, 2) C5-epimerization of some GlcA to IdoA residues 
and, finally, 3) incorporation of O-sulfate groups at various positions (Fig. 5A). 
N-deacetylation/N-sulfation is catalyzed by glucosaminyl N-Deacetylase/N-Sulfotransferases 
(NDSTs) that remove N-acetyl group from GlcNAc units and replace them with sulfate groups to 
form N-sulfated glucosamine units (GlcNS). NDST family has four family members, NDST-1, 
NDST-2, NDST-3 and NDST-4. The modifications by the NDST-enzymes occur in a block-wise 
fashion generating N-sulfated regions with GlcNS units and N-acetylated regions with GlcNAc 
residues. Due to the substrate specificity of the other modifying enzymes further modifications of 
the HS chains occur in or in the surrounding area of the N-sulfated regions (Ledin et al., 2004).     
The C-5 epimerase enzyme converts GlcA to IdoA. There is only one isoform of the C-5 epimerase. 
This enzyme has immense role in HS flexibility. Epimerization in HS chain makes the chains 
flexible which promotes the interactions with different proteins involved in for example cell 
signaling and cellular communication (Qin et al., 2015). 
Heparan sulfate 2-O sulfotransferase enzyme (only one isoform) is involved in transferring of 
sulfate groups to C2 position of IdoA and more rarely to GlcA. Sulfated IdoA residues play 
important roles in many HS-protein interactions like binding to different growth factors (Bethea et 
al., 2008).  
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Heparan sulfate 6-O sulfotransferase enzymes (three isoforms) transfer sulfate group to C6 position 
of GlcNS and GlcNAc units. 6-O sulfation of HS chain is important for many cellular processes 
such as HS binding to for example vascular endothelial growth factor and members of the FGF 
family (Nagai & Kimata, 2014).  
Heparan sulfate 3-O-sulfation is a late and rare modification of HS chains. HS-3-O 
sulfotransferases add one sulfate group at C3 position of glucosamine units in HS chains. There 
are 7 family members (HS-3-OST-1, -2, -3A, -3B, -4, -5 and -6). HS-3-OST-1 and -5 isoforms 
create HS with high affinity for antithrombin (that is mediating the anticoagulation activity of 
heparin) and herpes simplex virus 1 glycoprotein D of Type I herpes simplex virus (essential for 
viral invasion of the target cell) (Chen et al., 2003).   
 
 
Fig 5:  Schematic illustration of HS biosynthesis. A. Synthesis of the GAG-protein tetrasaccharide linker region by 
addition of xylose, two galactose residues and a GlcA to a serine residue on the core After addition of a GlcNAc 
elongation takes place by the alternating addition of GlcA and GlcNAc by EXT1/2. Modification starts with N-
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epimerization by the C5-epimerase and sulfations by 2-O-, 3-O- and 6-O-sulfotransferases (-OSTs).  B. Typical for 
HS is that not all potential sites are modified and that the modifications tend to be clustered. This results in the creation 
of different domains along HS chains, sulfated, non/sulfated and mixed sulfated/nonsulfated domains. Shown are also 
the binding sites for antithrombin and fibroblast growth factor 2. Figure provided by Prof. M. Kusche-Gullberg. 
 THE EXT-FAMILY 
The human exostosin (EXT)-family consists of five members; EXT1, EXT2 and three EXT-Like 
proteins, EXTL1, EXTL2 and EXTL3 (Busse-Wicher et al., 2014). EXT1 and EXT2 were first 
associated with the skeletal disorder Hereditary Multiple Exostoses, HME (describe below in 
EXOSTOSIN PROTEINS AND HEREDITARY MULTIPLE EXOSTOSES), hence the name 
exostosins.  Based on in vitro enzyme activities, all 5 family members are proposed to take part in 
HS biosynthesis (Fig. 6). However, only EXT1, EXT2 and EXTL3 have been shown to be 
necessary for HS chain elongation (Busse & Kusche-Gullberg, 2003).  
 
 
Fig. 6: EXT-proteins and their proposed roles in HS chain-elongation. A complex of EXT1 and EXT2 elongates 
the chain. EXTL3 initiates HS chains on a protein linkage tetrasaccharide. The roles of the EXTL1 and EXTL2 are 
unclear. Figure provided by Prof. M. Kusche-Gullberg. 
 
 EXT1 and EXT2 
Elongation of HS chains is believed to occur by alternating addition of GlcA and GlcNAc, from 
their respective UDP-sugars, by a complex of EXT1 and EXT2. They are type II transmembrane 
protein located in the Golgi with an N-terminal cytoplasmic tail, a transmembrane domain, and a 
large globular domain containing the enzymatic activity (Mccormick et al., 2000) (Fig. 7). In vitro, 
EXT1 alone has both GlcNAc-transferase and GlcA-transferase activity and can elongating HS 
chain without EXT2 (Busse & Kusche-Gullberg, 2003). The function of EXT2 is unexplained. 
After overexpression of EXT2 in mammalian cells no enhanced glycosyltransferase enzymatic 




?   
EXTL3
EXTL2?   
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activities was observed (Busse-Wicher et al., 2014). In contrast, siRNA silencing of either EXT2 
or EXT1 had similar effects on HS chain length, they become shorter (Busse et al., 2007). Knock-
out mice lacking EXT1 or EXT2 have the same phenotype. They lack HS chains and die during 
early embryonic development (Stickens et al., 2005). Thus, EXT2 clearly influences the catalytic 
activities of EXT1 and HS chain elongation. Studies have shown that EXT2 not only form a 
complex with EXT1 but also with NDST-1 and that NDST1 and EXT1 may compete for binding 
to EXT2 (Presto et al., 2008). 
 
 
Fig. 7: Schematic figure of a type II transmembrane protein. The EXT family members are type II transmembrane 
protein located in the Golgi with an N-terminal cytoplasmic tail, a transmembrane domain, and a large globular domain 
containing the enzymatic activity (Mccormick et al., 2000).  
 EXTL1 
EXTL1 can transfer one single GlcNAc to oligosaccharides mimicking the growing HS chains in 
vitro (Kim et al., 2001). EXTL1 exists in all mammals but absent in lower vertebrates. In humans, 
the EXTL1 expression seems to be restricted to a few tissues such as the brain, liver and kidneys 
and skeletal muscles (Wise et al., 1997). As HS is synthesized by all cells in the body and as EXTL1 
has a very restricted tissue expression EXTL1 does not seem to be necessary for or involved in HS 
biosynthesis. So far there is no publication of any model organism lacking EXTL1. 
 EXTL2 
EXTL2 is also present in all mammals but not in the lower vertebrates. EXTL2 is expressed in all 
human tissues and has two in vitro glycosyltransferase activities, transfer of GlcNAc and GalNAc 
units to the GAG-protein linkage tetrasaccharide (Busse-Wicher et al., 2014). EXTL2 knock out 
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mice produce large amounts of GAG chains indicating that in vivo, EXTL2 might has a role in 
HS chain termination (Katta et al., 2015).  
 EXTL3 
EXTL3 is expressed in all human tissues in both embryonic and adult lives and in all investigated 
species. EXTL3 has two in vitro glycosyltransferase activities, transfer of GlcNAc residues 
involved in initiation and elongation of HS chains. In vivo, EXTL3 appears only be involved in the 
initiation of HS chains by adding of the first GlcNAc to the GAG-protein-linkage tetrasaccharide 
(Busse et al., 2007). Similar to mice lacking EXT1 or EXT2, EXTL3 KO mice die during early 
embryonic development and lack HS.(Takahashi et al., 2009).   
 
 Exostosin proteins and hereditary multiple exostoses 
The name exostosin comes from the name used to describe the inherited bone disorder, hereditary 
multiple exostoses or osteochondromas (HME/MO), characterized by bony outgrowths around the 
growth plates in ribs, pelvis vertebrae and the long bones. The genes responsible for causing 
HME/MO were discovered by gene sequencing of affected patients (Stickens et al., 1996). The 
genes were named exostosin 1 (EXT1) and exostosin 2 (EXT2). Later it was found that these genes 
were involved in HS elongation (Lind et al., 1998). HME/MO is an autosomal dominant benign 
tumor characterized by multiple cartilage capped bony outgrowths (osteochondromas), which in a 
few cases (2 % of MO patients) is further transformed into chondrosarcoma or osteosarcomas. 
Incidence ratio of MO in population is about 1 per 50,000 live births. The exostoses give rise to 
chronic pain, limb deformities and neurological problems. The patients are heterozygote for the 
mutation and several different mutations in EXT1 and EXT2 have been reported in HME patients. 
The mutations are predominantly found in exons and randomly distributed over the entire EXT1 
gene, whereas EXT2 mutations are more commonly found towards the N-terminal part of the 
protein (Pacifici, 2017). The EXTL proteins belong to the EXT-family based on amino acid 
sequence homology with EXT1 and EXT2 but are not associated with HME/MO (Busse-Wicher 
et al., 2014).  
  




EXT1 and EXT2 proteins play major roles in HS chain biosynthesis. The specific focus of this 
study was to investigate the individual roles of EXT1 and EXT2 in HS elongation. It is suggested 
that EXT1 and EXT2 form a co-polymerase complex that elongates HS but the individual role of 
the two proteins in HS biosynthesis is not known. Deletion of either EXT1 or EXT2 in mice and 
human cells have shown that both proteins are necessary for HS chain elongation. Previous in vitro 
data shows that EXT1 has high enzyme activities related to HS elongation whereas the enzyme 
activities of EXT2 are very weak. Previously, it has been difficult to pinpoint the individual 
activities of EXT1 and EXT2 as the EXT proteins tend to associate with each other and to remain 
associated also after purification of recombinant proteins. The generation of cells lacking EXT1 or 
EXT2 has made it possible to study the individual activities of EXT1 and EXT2 by expressing 
EXT1 in a cell lacking EXT2 and EXT2 in a cell lacking EXT1. 
 
Overall Aim of this study:  
To clarify the role of EXT2; is it a glycosyltransferase or a chaperon?  
 
Specific aims: 
1. To determine transferase activities of EXT2 protein  
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3 RELEVANCE TO GLOBAL HEALTH  
 
The interactions of HSPGs with different protein ligands clearly influence global health. By 
interacting with growth factors and other signaling molecules, HS controls processes in 
pathogenesis of many disorders world wide including, inflammatory diseases, eye diseases, cancer, 
viral and bacterial infections (Lindahl & Kjellén, 2013). This has a significant impact when 
considering the high burden of these diseases world-wide. The key to understand the function of 
EXTs and HS in disease is to clarify how they are regulated in normal physiology. The results from 
this project will help us to better understand how EXT protein interactions are regulated and HS 
chain length determined in normal cells. This knowledge is essential for our understanding of what 
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4 MATERIALS  
 
Table 1. Cell lines 
Cell line Provided by 
EXT1KO B16F10 mouse melanoma cell (P 16) Dr. Christian Gorzelanny, PhD 
University Hospital Hamburg-Eppendorf 
Department of Dermatology 
Germany 
EXT2KO B16F10 mouse melanoma cell 
WT B16F10 mouse melanoma cell (P 39) 
EXT1KO MV3 human cell (P 3) 
WT MV3 human cell 
 
Table 2. Cell culture reagents and materials  
Reagent Supplier Cat. no/Ref. no 
Dulbecco’s modified eagle medium (DMEM) 
GlutaMAX 
Gibco Ref: 31966-021 
Fetal bovine serum (FBS) Corning Ref: 35-015-CV 
Antibiotic-Antimycotic (AA)  Gibco Ref: 15240-062 
Dulbecco´s phosphate buffered saline (PBS) Sigma-Aldrich Cat no: D8537 
0.05% Trypsin-EDTA  Sigma-Aldrich Ref: 25300-054 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich  Cat no: D2660 
RPMI-1640 medium with  
25mM HEPES without L-glutamine. 
Sigma-Aldrich Cat no: R5886 
Cell culture flasks (25 and 75 cm2) Thermo Scientific Cat.no: 156367 & 
156499 
Nunclon Cell culture dishes (25 cm2) Thermo Scientific Cat.no: 150288 
 
Table 3. Transfecting agents  
Name Supplier Cat. no/Ref. no 
Human tGFP-tagged EXT2 (NM_207122) 
plasmid DNA 
Origene Cat. no: RG204067 
Human Myc-DDK-tagged EXT1 
(NM_000127) plasmid DNA 
Origene  Cat. no: RC200644 
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Table 4. Chemicals and materials for transferase assays and BCA protein assay 
Reagent Supplier Cat. no/Ref. no 
Buffer mix (4.25 µl/25 µl assay) 0.2 M MgCl2, 0.1 M CaCl2, 2 M NaCl, 
1 M Hepes pH 7.4 and freshly prepared  
GlcNAc[GlcA-GlcNAc]n GlcA acceptor substrates Made from Escherichia coli K5 
capsular polysaccharide in the lab of M. 
Kusche-Gullberg 
[GlcA-GlcNAc]n GlcNAc acceptor substrates 
UDP-[3H]GlcNAc (100:1 ratio labeled and 
unlabeled UDP-GlcNAc, final conc. of UDP 
[3H]GlcNAc, 0.1 µCi/µl)  
PerkinElmer Ref: NET434050UC 
UDP-[14C]GlcA (100:1 ratio labeled and unlabeled 
UDP-GlcA, final conc. of  UDP-[14C]GlcA, 0.02 
µCi/µl]. 
PerkinElmer Ref: NEC414050UC 
Price BCA Protein Assay Kit Thermo 
Scientific 
Ref no: 23225 
 
Table 5. Antibodies 
Primary antibody Supplier Cat. no/Ref. no 
Mouse monoclonal anti-turboGFP antibody Origene Cat no: TA150041 





Cat no: sc-332233 
 





Cat no: sc- 516102   
 
Table 6. Chemicals and materials for SDS acrylamide gel 
Reagent Supplier Cat. no/Ref. no 
30% Acrylamide/ Bis Solution 37.5:1 BIO-RAD Cat: 1610158 
Tris-HCl 2M pH= 8.8 
 
 Made in lab 
SDS 20% BDH 
Biochemical 
Ref: 44215HN 
N,N,N,N- tetramethylethylenediamine (Temed) 
approx. 99%  
Sigma-Aldrich Cat no: T9281 
Ammonium Persulfate 10% Sigma-Aldrich Cat no: A3678 
TX sample buffer (4x) BIO-RAD Cat no: 1610791 
DL-Dithiothreitol, MW=154.25 g/mol Sigma-Aldrich   Cat no: D9779 
Magic marker XP protein standard Invitrogen Ref: P/N LC 5602 
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Precision plus protein standard (Dual color) BIO-RAD  Cat no: 1610374 
 
Table 7: Materials used in Western blotting  
Materials Supplier Cat. no/Ref. no 
Instant dried Skimmed Milk  TESCO  
Triton X-100 Sigma-Aldrich  Cat no: T8787 
Tween 20 Sigma-Aldrich Cat: P 2287 
Trizma Base Sigma-Aldrich Cat no: T1503 
Pierce™ ECL western blotting substrate Thermo Scientific  Ref: 32106 
 
Table 8: Materials used for gel chromatography analysis. 
Materials Supplier Cat. no/Ref. no 
Sephadex G-25 Superfine GE Healthcare.  Cat no: 17-0031-01 
polypropylene cap.Simport™Scientific 6.5mL 
HDPE Snaptwist™ Scintillation Vials 
  
1 M NaCl Sigma-Aldrich Cat no: 31434 
Optiphase Hisafe 3 scintillation cocktail PerkinElmer  1200.437 
 
Table 9. cDNA preparing reagent and PCR reagents 
Reagent Supplier Cat. no/Ref. no 
5x iScript Reaction Mix BIO-RAD   Cat no: 1708891 
iScript Reverse transcriptase BIO-RAD   Cat no: 1708891 
Sybr green supermix BIORAD Cat no: 1708882 
 
Table 10: Primers used in RT-PCR 








 TGGGATCGAGGAACAAATCACC  TGCCGGTAAGTCCAGGTAGAA 
Beta Actin  GGC TGT ATT CCC CTC CAT CG CCA GTT GGT AAC AAT GCC ATG 
T 




GCT CTT GTC TCG CCC TTT TGT TGG TGC AAG CCA TTC CTA CC 
 





AAG CAC CAG GTC TTC GAT 
TAC C 
GAA GTA CGC TTC CCA GAA CCA 
hHPRT CTT CCT CCT CCT CCT GAG CAG TCG AGC AAG ACG TTC AGT CC 
POLR2F CAC CCC CCA GTC TTC ATA GC CCC GAA AGA TCC CCA TCA T 
 
 
Table 11: Materials used in immunofluorescence   
Name Supplier Cat. no/Ref. no 
Collagen type I Advance Bio Matrix Cat no: 5005 
Primary antibody: Mouse 
monoclonal turboGFP antibody 
Origene TA150041 
Secondary antibody: Alexa Fluor 
488-conjugated AffiniPure Goat 




Cat no: 115-545-146 
4% PFA Paraformaldehyde (PFA) Thermo Scientific Ref: 28908 
4′,6-diamidino-2-phenylindole 
(DAPI) 
Invitrogen Ref: P36935 
 
Table 12: Materials used for metabolic labeling of cells   
Name Supplier Cat. no/Ref. no 
DEAE-Sephacel Amersham Biosciences Cat no: 17-0500-01 
PD 10 columns GE Healthcare Cat no: 17-0851-01 
[3H]Glucosamine-HCl PerkinElmer Cat.no: NET190A 
Heparin   
AgNO3 Sigma-Aldrich Cat.no: 7761-88-8 
Superose 6 GE Healthcare Cat.no: 17-5172-01 
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5 METHODS 
 Cell culture  
To ensure sterile conditions and prevent contamination all cell culture work was performed in a 
laminar flow bench with HEPA filter, and all equipment and work areas were disinfected with 70 
% ethanol before starting work. The cells were grown in monolayer in culture flasks in Dulbecco’s 
Modified Eagle Medium (DMEM), supplemented with 10% (v/v) fetal bovine serum 1% antibiotic-
antimycotic solution (10,000 units/ml penicillin, 10,000 µg/ml streptomycin and 25 µg/ml Gibco 
Amphotericin B) and 1% L-glutamine at 37 °C, in a standard 5% CO2 cell culture incubator.  
 Cell splitting  
Cell splitting, also called cell passaging, is an essential process for the growth and multiplication 
of cells. Once the available substrate surface is covered by cells (a confluent culture), growth slows 
down and eventually ceases. To ensure that the cells stay alive, the cells were split, diluted and 
transferred to a new culture flask. The medium in the cell culture flask was removed and the cells 
were washed three times with 5 ml sterile Dulbecco’s phosphate buffered saline (PBS) at room 
temperature. To detach the cells from the flask, 1 ml of trypsin was added and cells incubated 3 to 
4 minutes at 37 °C. When the cells rounded up and detached, trypsin was inhibited by the addition 
of 6 ml of the pre-warmed cell culture medium. The detached cells were transferred to new cell 
culture dishes. Due to fast growing nature of B16F10 mouse melanoma cells, they were split at a 
ratio of 1:10 every day to prevent over-confluency.  
 Cell Freezing   
Freezing down of cells is an important factor to maintain the cell line at a low passage number, 
without contamination and genetic drift. Continuous growth of cells increases the passage number 
of the cell line increases the risk of a cellular alteration and contamination. Cells at 80%-90% 
confluency were trypsinized, resuspended in culture medium and centrifuged at 1000 rpm for 5 
min. The supernatant was discarded, and the cell pellet was resuspended in cold freezing medium, 
containing 10% DMSO, 20% FBS and 70% culture medium. The cell suspension was then 
aliquoted into Cryovial tubes and stored in a Cool Cell box (Biocision) at -85˚C for a few days, 
and then transferred to tank of liquid nitrogen for long-term storage. 
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 Cell transfection 
Full-length C-terminal Turbo GFP-tagged EXT2 or full-length C-terminal Myc-DDK-tagged 
EXT1 in the PCMV-6-AC-GFP plasmid vector were transiently transfected into mouse B16-F12 
and human MV3 melanoma cell lines. Cells were cultured to 80 % confluent in T75 cell culture 
flasks. After trypsinization, cells were resuspended in 10 ml of culture medium. Next, cells were 
gently seeded in pairs of different concentrations in 6 cm petri dishes and incubated at 37°C 
overnight. The following day, the dishes with approximately 50-60% cell confluency were selected 
for transfection. Cells were transiently transfected using Lipofectamine 2000 (Invitrogen). Briefly, 
cells were transfected with 1:3 ratio of plasmid (µg) and Lipofectamine 2000 (µl). Plasmid DNA-
Lipofectamine complexes were added dropwise to the cells and cells incubated at 37°C. After 5 
hours, 3 ml of cell culture medium containing 20% FBS was added to the cells and the cells were 
further incubated for 16-18 hours. Then, cells were extracted for transferase assay, protein analysis 
and total RNA isolation. Cells treated with only lipofectamine were used as controls. 
 
 Protein expression analysis 
The culture dish was washed twice with warm PBS. Thereafter, 0.25 ml of cold PBS was added, 
and cells were detached from the surface using a cell scraper. The total lysate was collected and 
placed on ice. Samples were centrifuged at 1300 rpm for 10 min at 4 °C. The supernatant was 
discarded. The pellet was resuspended in 80 µl of lysis buffer containing protease inhibitor cocktail 
and incubated on a rotating shaker for 30 min at 4 °C. The sample was then centrifuged for 30 min 
at 13000 rpm at 4 °C. The supernatant was collected, and an aliquot immediately used for 
transferase assay and the remaining lysate for Western blot and BCA protein analysis. 
 
 Glycosyltransferase assays 
To investigate if the expressed EXT1 and EXT2 were able to transfer a single sugar residue to an 
acceptor oligosaccharide (Fig. 8), cell lysates were centrifuged, and the supernatants immediately 
used for transferase assays. Lysates, corresponding to approx. 10-40 µg protein were incubated 
over-night at 37°C with 0.125 µCi of 14C- or 3H-labeled UDP-sugars (62.5 µCi/µmol; prepared by 
mixing radiolabeled and unlabeled UDP sugars) and 45 µg of oligosaccharide acceptor in a total 
volume of 25 ul of 10 mM MgCl₂, 60 mM NaCl, 20 mM MnCl2, 5 mM CaCl₂ and 20 mM Hepes, 
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pH 7.4 (final concentrations). To measure GlcA-transferase activity, 14C -labeled UDP-GlcA and 
[GlcNAc-GlcA]n- oligosaccharide acceptors were used. To measure GlcNAc-transferase activity, 
3H-labeled UDP-GlcNAc and GlcA-[GlcNAc-GlcA]n acceptors were used (Fig. 8). The reaction 
products were analyzed by gel chromatography and quantified by scintillation counting.  

















Fig. 8: Schematic figure showing the principal of single sugar transferase assays. Cell lysate were incubated with 
polysaccharide acceptors (GlcA-[GlcNAc-GlcA]n or [GlcNAc-GlcA]n and radiolabeled UDP-sugar. Active proteins 
transfer a single sugar unit to the acceptor molecule resembling the unmodified HS chain. The figure was provided by 
Prof. M.Kusche-Gullberg. 
 
 Western blot analysis.  
Cell lysates (described in protein extraction section) were used for BCA protein assay, SDS-
PAGE and Western blot analysis. 
 BCA protein assay 
Total protein concentration of whole cell lysate was measured using Pierce™ BCA Protein Assay 
Kit following the manufacturer’s protocol. Samples were prepared at 1:10 dilution using Milli-Q 
water. Serial dilutions of BSA (0, 25, 125, 250, 500, 750 and 1000 µg/ml) measured in duplicates 
were used to generate a standard curve. The concentration of samples was measured at 22.7°C at 
562 nm absorbance using a Spectra Max Plus 384 Microplate Spectrophotometer. 
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 SDS PAGE electrophoresis  
SDS PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) is used for separation of 
proteins by molecular weight in response to a supplied electric field. 50 µg of each protein samples 
were mixed with 10 µl of TX sample buffer (4x) containing 200 mM DL-Dithiothreitol (DTT) and 
the total sample volume was made up to 40 ul using sterile distilled water. The samples were 
separated on a 10% SDS-PAGE (using Mini-Protein short glass plates of 1.5 mm thickness, 
BioRad) for approximately 75 minutes at 125V. Magic marker (Invitrogen) and Precision plus 
protein standard (Dual color) were used as molecular weight markers.  
Transfer of the proteins to an iBlot Gel transfer nitrocellulose membrane (Invitrogen) was done 
using an iBlot 2 Gel Transfer Device (semi-dry transfer device). After transfer, the membranes 
were stained with 0.1% (w/v) Ponceau in 5% acetic acid for approx. 5 minutes. Ponceau red is a 
red solution that reversibly binds to proteins. This gives information about the efficiency of the 
transfer. The membrane was then de-stained with 1x-TBS/T (1x TBS+ 0.1% Tween 20). To prevent 
unspecific binding of the antibodies to the membrane the membrane was blocked in 5% skimmed 
milk dissolved in TBS-T at room temperature for 1 hour. Thereafter, the blot was incubated at 4°C 
with the primary antibody overnight on a rocking table. For detection of tGFP-EXT2 a primary 
mouse monoclonal turbo-GFP antibody (1:200 dilution, Origene) was used. For detection of myc-
EXT1 a primary mouse myc antibody (1:500 dilution, Sigma-Aldrich) was used. GAPDH mouse 
monoclonal antibody (1:2000, Santa Cruz) was used as an internal loading control. Next, the 
membrane was washed 3 x 10 min using 1 x TBS-T to wash away unbound antibodies.  The blot 
was then incubated with the secondary antibody Mouse IgG- BP-HRP (Horseradish peroxidase, 
1:5000) for 1 hour at 37 °C. Finally, the membrane was washed 3 x 10 min in 1X TBS-T and the 
bands detected using ECL Western Blot Detection kit (Pierce). The kit detects the HRP-labeled 
secondary antibodies bound to primary antibodies, resulting the formation of a fluorescent product 
which is visualized using Gel Doc Imaging system (BIO-RAD). The bands were quantified using 







23 | P a g e  
 
 Gel Chromatography 
Gel chromatography is a technique to separate molecules according to their difference in molecular 
weight or size. The molecules in the sample are pumped through columns containing such 
microporous gels. Larger molecules elute first and is followed by smaller molecules. 
 Gel column preparation 
The column was prepared using Sephadex G-25 Superfine gel filtration resin. 15g of Sephadex 
superfine was mixed with 200 ml of distilled and the resin was allowed to swell overnight to form 
a gel. The following day, the gel was pipetted into the column without getting any air bubbles. 
 Sephadex G-25 gel chromatography 
To separate oligosaccharide acceptor molecules that have incorporated a radiolabeled sugar (Fig. 
9) from unincorporated radiolabeled UDP-sugars, the assay mix was loaded onto Sephadex G-25 
gel chromatography column run in 1 M NaCl. Loading of samples were followed by rinsing the 
tube with 1 M NaCl to ensure that the entire sample was loaded into the gel. The eluates were 
collected in Scintillation Vials for 4 min/vial. 3 ml of Optiphase Hisafe 3 scintillation cocktail was 
added in each tube. Radioactivity was detected by the scintillation counting by Liquid Scintillation 
Analyzer supplied (Packard). 
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Fig. 9: Figure shows the principle of gel chromatography. Blue indicates oligosaccharide acceptor molecules that 
have incorporated a radiolabeled sugar and red, free, unincorporated, labeled UDP-sugars. Modified from 
https://www3.nd.edu/~aseriann/CHAP6B.html/sld002.htm 
 
 Gene expression analysis by RT-PCR 
 RNA extraction 
RNA was extracted from ~80-90% confluent cells grown in cell culture petri dishes with a surface 
area of 25 cm². The RNeasy Mini kit (Qiagen) was used to isolate RNA, following the protocol of 
the manufacturer. The total amount and purity of RNA was determined using NanoDrop 2000 
Spectrophotometer (Thermo Scientific). 
 cDNA synthesis  
cDNA was synthesized using iScript™ cDNA synthesis Kit (BioRad) used for reverse transcription 
of aliquots of 1 µg RNA to cDNA, following the manufacturers protocol. Briefly, 4 µl of 5x- iScript 
reaction buffer mix and 1µl of iScript reverse transcriptase were together added to the purified 
RNA samples, and the reaction mixture was incubated in the Thermal cycler to synthesize 
complementary DNA strands.  The following reaction conditions were used: primer annealing at 
25°C for 5 min, reverse transcription of RNA at 46°C for 20 min, enzyme inactivation at 95°C for 
5 min and optional step- hold at 4°C. The synthesized cDNA was diluted at 1:9 ratio using Milli-
Q water.  
 Quantitative real Time-Polymerase chain reaction (RT-PCR) 
Quantitative-real Time-Polymerase chain reaction (RT-PCR) is used to analyze the degree of gene 
expression by determining the amount of amplificated sample during each cycle, in real time, with 
forward and reverse primers of the target gene. Briefly, 6 µl iQSYBR Green supermix (Bio-Rad) 
was mixed with 0.5µl forward primer and 0.5 µl reverse primers (for list of primers see Table 11), 
and 5 µl of cDNA sample. The reaction mixture of each sample loaded in triplicates in a 384-well 
plate. The plate was covered and centrifuged 2 min at 2000 rpm and run on LightCycler® 480 
system machine (Roche). The expression level of the EXT mRNA was normalized to that of the 
reference gene mRNA level. The relative expression levels were calculated using the 2-ΔΔCT method 
(Livak & Schmittgen, 2001). 
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 Immunofluorescence staining  
Immunofluorescence staining of transiently transfected cells was done to see the transfection 
efficiency of EXT1KO and WT cells transfected with tGFP-tagged EXT2 DNA. The transfected 
cells were stained with an anti-tGFP antibody and observed under fluorescence microscope. 
 Cell plate preparation 
Cover slips were prepared by washing with soap for 10 min followed by rinsing with water and 
70% ethanol. After drying the coverslips were inserted into a 12-well plate, coated with collagen 
type I (100 µg/ml) and incubated for 1 hour at 37°C and then washed 3 x 5 min with PBS. 
 
 Cell staining  
Cells in suspension were counted using Casy Modell TT, SCHÄRFE System. EXT1KO and WT 
cells were seeded on the prepared cover slips, 20 000 cells in each well. After 24 hours the cells 
were transiently transfected with the tGFP tagged EXT2 DNA plasmid. Control cells were treated 
with only Lipofectamine 2000. After 5 hours, 3 ml of 20% FBS medium was added into each well 
and the plate incubated 16-18 hours more. After 24 hours of transfection cell were stained. To stain 
for tGFP, cells were washed three times in PBS, fixed with freshly prepared 4% PFA 
(Paraformaldehyde), washed three times with PBS, permeabilized in 0.1% TX-100 for 15 min at 
room temperature and blocked with 10% bovine serum albumin in PBS for 1 hour.  Cells were then 
incubated with the anti tGFP monoclonal antibody (1:200) at room temperature for 45 min. 
Thereafter, cells were washed 3 x for 10 min at room temperature using 0.1% PBS-Tween-20 and 
incubated with the secondary antibody Alexa fluor goat anti-mouse 488 (1:400). Cells incubated 
with only the secondary antibody was used as controls. After addition of the secondary antibody 
the plate was kept in dark for 1 hour at room temperature and then washed 3 x 10 min with PBS 
containing 0.1% Tween-20. Cells were mounted using ProLong Gold antifade reagent with DAPI 
(Invitrogen) and were incubated overnight. The following day, slides were observed under Zeiss 
Axioscope microscope equipped with optics for observing fluorescence and captured using a digital 
AxioCam MRm camera in a dark room at 40x magnification. 
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 Metabolic labeling with 3H-glucosamine and analysis of heparan sulfate 
structure  
This experiment was done to rescue HS from knock-out cells by reintroducing of corresponding 
EXTs. B16F10 mouse melanoma EXT1KO cell was transfected with myc-tagged EXT1 plasmid 
DNA and EXT2 KO cell was transfected with tGFP-tagged EXT2 plasmid DNA. Cells were 
transfected as described in “Cell transfection” section. 
 3H-glucosamine metabolic labeling 
After 24 hours of transfection, cells were metabolically labeled by replacing the medium with 4 ml 
fresh medium (DMEM and 10 % FCS, without antibiotics), contain approximately 50 μCi/ml 3H 
Glucosamine-HCl. After 24 hours the medium was removed and stored at -20°C. Cells were 
washed with 2 x 5 ml PBS and then solubilized in 1 ml solubilization buffer (1%TX-100, 0.15 M 
NaCl, 50 mM Tris/HCl pH 7.4) for at 4 hours at 4°C on a rocking table. Cells were harvested using 
a cell scraper, transferred to an Eppendorf tube, and collected by centrifugation at 2000 rpm for 15 
min at 4°C. The supernatant was transferred to a new tube and an aliquot used for protein 
determination using the BCA protein determination kit. The remaining supernatant was alkali 
treated to release GAGs from the protein.  
 Alkali treatment to release O-linked oligo and polysaccharides from proteins  
NaOH, in a final concentration of 0.5 M, was added to the supernatant to separate the GAG chains 
from the core protein. After overnight incubation at 4°C, the samples were neutralized with HCl. 
The pH was adjusted to approximately pH 8.0. 
  Isolate free chains on DEAE-Sephacel 
Diethylaminoethyl (DEAE)-Sephacel (Amersham Biosciences) is a positively charged ion-
exchange resin that retains negatively charged molecules.  Columns were made with 500µl DEAE-
Sephacel equilibrated in 5 ml equilibration buffer (0.05 M Tris/HCl pH 8.0 or 7.5, 0.15 M NaCl, 
0.1% TX-100). 2 mg heparin was added to the DEAE-Sephacel columns to prevent unspecific 
binding and excess heparin was eluted with 2 M NaCl. Then columns were equilibrated in 
equilibrated buffer. The samples were diluted to a final concentration of 0.15 M Cl- in 0.02 M 
Tris/HCl pH 8.0 and added to the column. and the column was washed 10 times with 500 µl 
portions of the equilibration buffer and the eluate collected in 10 Eppendorf tubes. Then column 
then washed 10 times with 500 µl portions of 0.05 M acetate pH 4.0, 0.15 M NaCl, 0.1% TX-100. 
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Followed by a third washing step was carried out 10 times with 500 µl portions of 0.05 M Tris/HCl 
pH 8.0 or 7.5. Finally, the GAG chains were eluted by stepwise elution with 10 times x 500 µl 
portions of 2 M NaCl.  Radioactivity was measured for each fraction. 5 µl from each fraction, 3 ml 
of Optiphase Hisafe 3 scintillation cocktail was added and the radioactivity measured by a 
scintillation counter. Radioactive positive fractions in the 2 M NaCl eluate were pooled and 
desalted on PD-10 gel filtration columns. 
 Desalting using PD 10 Columns 
To separate GAG chains from unwanted salt, the samples were transferred to a PD10 column (GE 
Healthcare) which is a pre-packed SephadexTM G-25 resin. The column was first washed with 30 
ml H2O. Then 1 mg heparin was added to the column to prevent unspecific binding followed by 
washing with 50 ml H2O. Then the sample was added to the column and the flow through collected. 
The GAG chains were eluted with 12 x 0.5 ml H2O. Fractions of 0.5 ml were collected and 5 µl 
from each eluted were analyzed for 3H-radioactivity by scintillation counting. To analyze for salt 
(NaCl), 20 µl of each fraction was transferred to a transparent Eppendorf tube. After addition of 
0.1% AgNO3, salt will be visible as a white precipitate (AgCl2). Salt-free 
3H-positive fractions 
were pooled and quantified. The pooled samples were freeze dried and then resuspended in water 
to a volume of about 500 µl in total.  60 000 DPM from each sample, was transferred into a 1.5ml 
tube, dried in a SpeedVac (Thermo Savant SPD1010 SpeedVAC) and resuspended in 200 µl H2O.  
 Chondroitinase ABC digestion 
To remove CS from the purified samples, an aliquot (60 000 DPM) of the labeled samples was 
digested with chondroitinase ABC (Sigma) into disaccharides. Digestion was carried out overnight 
at 37°C in a buffer containing 100 µg chondroitin sulfate, 50mM Tris-HCl pH 8.0, 30 mM Na-
acetate, 0.1mg/ml bovine serum albumin and 0.2 units chondroitinase ABC. After overnight 
incubation, the sample was transferred to -20°C for 2 hours to inhibit the remaining enzyme 
activity. The sample was then centrifuged for 10 minutes at maximum speed and transferred to a 
clean Eppendorf tube. Next, 300 µl 0.5 M NH4HCO3 was added to the sample which was then 
centrifuged again to precipitate and remove any impurities. The samples were then analyzed using 
a Superose 6 HPLC gel filtration column.  
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 Superose 6 HPLC gel filtration column 
Superose 6 is a HPLC gel filtration column (Amersham Biosciences) used for determining HS 
chain length. After addition of 300 µl 0.5 M NH4HCO3, the samples were centrifuged to precipitate 
and remove any impurities before they were analyzed using a Superose 6 HPLC gel filtration 
column. The smaller fragments (CS disaccharides) are retained longer in the beads, whereas the 
larger fragments (HS chains) pass alongside the beads, thus exiting the column first. The samples 
were collected in 60 fractions of 500 µl and the radioactivity measured by scintillation counting. 
  




EXT1 and EXT2 protein have major role in HS chain elongation by adding GlcA and GlcNAc in 
an alternative manner to the growing HS chain. Previous results have shown that both EXT1 and 
EXT2 are necessary for chain elongation in vivo. In in vitro assays, EXT1 has readily detectable 
enzyme (glycosyltransferase) activities but, it has been difficult to determine the enzyme activities 
of the EXT2 protein. This thesis deals with the individual roles of EXT1 and EXT2 in HS chain 
elongation with special focus on the enzymatic activities of EXT2. EXT enzymatic activities were 
examined using mouse or human melanoma cells lacking EXT1 (EXT1 knock-out, EXT1KO) or 
EXT2 (EXT2KO). Previous analysis in the lab of M. Kusche-Gullberg have shown that both 
EXT1KO and EXT2KO cells completely lack HS. To observe the individual functions of EXT1 
and EXT2 and to prevent contribution of endogenous proteins, EXT1KO cells and EXT2KO cells 
were transiently transfected with plasmids expressing full-length human TurboGFP (tGFP)- tagged 
EXT2 and full-length human C-terminal myc-DDK-tagged EXT1, respectively. For control, wild 
type (WT) cells were also transfected and analyzed for activity.  
 
  EXT1 deficient (EXT1KO) B16F10 mouse melanoma cells transfected with 
tGFP tagged EXT2 plasmid DNA 
 Protein expression analysis by Western blotting.  
Full-length tGFP-EXT2 was transiently transfected into WT (WT+ EXT2) and EXT1KO (EXT1 
KO+EXT2) B16F10 mouse melanoma cells using Lipofectamine. WT cells and EXT1KO cells 
treated with only Lipofectamine were used as controls, WT control and EXT1KO control, 
respectively. The experiment was repeated four times and the level of overexpression analyzed by 
Western blotting (WB) of cell lysates using an antibody to tGFP (Fig. 10A) and the expressed 
proteins quantified relative to GAPDH (Fig. 10B). tGFP-tagged EXT2 has an apparent molecular 
weight of 108 kDa while the weight of GAPDH is 36 kDa. Comparisons of the expression levels 
of WT+ EXT2 with the expression of the EXT1 KO+EXT2 cells, showed that the relative values 
of expression of tGFP-EXT2 protein in EXT1 KO+EXT2 cells were much lower than in WT+ 
EXT2 cells.  
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Fig. 10: Western blot analysis (A) and quantification of the expressed tGFP-EXT2 protein (B). (A) Cell extracts 
(50 µg cellular protein /lane) from EXT2 transfected cells and transfection reagent only treated control cells were 
separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (see “Methods”). The expressed 
proteins were detected with antibodies against tGFP (1:200) and GAPDH (1:2000) and visualized by 
chemiluminescence. Shown is one representative blot out of four separate experiments. The positions of molecular 
size standards (in kDa) are indicated. (B) The band intensity of detected proteins was quantified for all four experiments 
by Imagej software and presented in the bar graphs as relative to GAPDH.  
 
 
 EXT2 mRNA expression levels in WT control, EXT1KO control, WT+ EXT2 and 
EXT1KO+EXT2 B16F10 mouse melanoma cells  
To determine if the low amounts of expressed tGFP-EXT2 protein in EXT1KO+EXT2 cells were 
caused by an inhibition at the protein level (improper translation, folding or transport of the EXT2-
protein) or a lower transfection efficiency, the relative amounts of EXT2 mRNA were determined 
by real-time PCR. RNA was extracted from the four different cell-types and cDNA was transcribed 
by reverse transcription and analyzed by PCR. The experiment was repeated three times. The 
expression level of EXT2 in EXT1KO control cells was similar to like WT control cell, showing 
that treatment with lipofectamine did not affect endogenous levels of EXT2. Similar to the results 
from protein analysis, EXT2 expression level was much higher in WT transfected cells than in 
EXT1KO cell transfected cells (Fig. 11), indicating that the transfection efficiency in EXT1KO 
cells was reduced compare to WT+EXT2 cells.  
 
A B 
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Fig. 11: mRNA levels of EXT2 protein in transfected and non-transfected B16F10 mouse melanoma cells. Cell 
were transiently transfected with tGFP-tagged EXT2 (WT+ EXT2 and EXT1KO +EXT2) or treated with transfection 
reagent only (WT control and EXT1KO control) as described in “Methods”. 24 hours after transfection relative mRNA 
levels were determined by real time PCR and normalized to those of A) b-actin and B) S26. mRNA levels are expressed 
relative to the expression of the WT control that was set to 1. The error bars in A and B represent the mean from three 
independent transfections. Each measurement was performed in triplicate. 
 
 
 Glycosyltransferase activity in WT control, EXT1KO control and EXT1KO+EXT2 
B16F10 mouse melanoma cells  
To analyze the catalytic properties of EXT2 protein, two different in vitro transferase assays were 
employed, both of which quantify the transfer of single sugars to acceptor molecules. 
Oligosaccharides derived from Escherichia coli K5 capsular polysaccharide were used as acceptor 
molecules. The K5 polysaccharide has the same [GlcA-GlcNAc]n, structure as nonsulfated HS. 
K5-oligosaccharides with non-reducing terminal GlcA or GlcNAc residues thus serve as acceptors 
in the GlcNAc- and GlcA-transferase reactions (see “Methods”, Fig. 8). The in vitro GlcA-
transferase activity of EXT1KO+EXT2 cells were found to have increased approximately 20-fold 
as compared to EXT1KO cells (Fig. 12B).  This result indicates that EXT2 protein has GlcA 
transferase activity. 
A B 
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Fig. 12: GlcA transferase activities in EXT2 transfected and non-transfected B16F10 mouse melanoma cells. 
Crude cell-lysates from cells, as indicated in the figures, were incubated with radiolabeled UDP-GlcA and unlabeled 
acceptor oligosaccharides with a nonreducing end GlcNAc and assayed for single-sugar transfer of GlcA to the 
acceptor. A) Gel chromatography of acceptor oligosaccharides with added GlcA (eluting around fractions 5-15). 
Material eluting after fraction 15 represent unincorporated labeled UDP-GlcA.  B) Bar graphs show the incorporation 
of GlcA as radioactivity (cpm)/ mg protein. The figure is representative mean ±SD from two independent experiments. 
 
In contrast to the clear increase in GlcA-transferase activity there were no significant difference in 
GlcNAc-transfer between EXT1KO+EXT2 and EXT1KO cells. However, the KO cell showed 
some GlcNAc transferase activity (Fig. 13) which was unexpected. The GlcNAc transferase 
enzyme activity in EXT1KO calls may be due to the activity of EXTL3 as total cell lysate 
containing EXTL3 is known to transfer GlcNAc to K5 acceptors (Busse et al., 2007).  
 
 













Fig. 13: GlcNAc-transferase activities in EXT2 transfected and non-transfected B16F10 mouse melanoma cells. 
Crude cell-lysates from cells, as indicated in the figures, were incubated with radiolabeled UDP-GlcNAc and unlabeled 
acceptor oligosaccharides with a nonreducing end GlcA and assayed for single-sugar transfer of GlcNAc to the 
acceptor. A) Gel chromatography of acceptor oligosaccharides with added GlcNAc (eluting around fractions 5-15). 
A B 
A B 
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Material eluting after fraction 15 represent unincorporated labeled UDP-GlcNAc. B) Bar graphs show the 
incorporation of GlcNAc as radioactivity (cpm)/ mg protein.  The figure is representative mean ±SD two independent 
experiments. 
  
 Immunofluorescence staining 
To further investigate the low transfection efficiency of EXT1KO+EXT2 cells, EXT1KO+EXT2 
and WT+EXT2 cells were stained using an antibody against the tGFP-tag. Transfected cells were 
fixed and stained with the primary antibody, mouse monoclonal anti turbo GFP (1:200) and the 
secondary antibody, Alexa Fluor goat anti-mouse 488 (1:400). Stained cells were mounted with 
DAPI to visualize nuclei. Immunofluorescence staining showed that the level of overexpression 
was relatively low in EXT1KO+EXT2 cells (Fig. 14). Only few EXT1KO+EXT2 cells expressed 
the tGFP-tagged EXT2.  
 
                
 
 
Fig. 14: Immunofluoresence staining of EXT2 transfected cells. EXT1KO and WT B16F10 cells were transiently 
transfected with the full-length tGFP-EXT2 expression plasmid. The transfected cells were fixed and stained for EXT2 
(green) and the nuclei counterstained with 4',6'-diamino-2-phenylindole (DAPI, blue) as described in Methods section.  
 
 EXT1 deficient MV3 human cells transfected with tGFP tagged EXT2 
plasmid DNA 
 
The results after transfection of the B16F10 EXT1KO cells with tGFP tagged EXT2 plasmid DNA 
resulted in GlcA-transferase activity, indicating that EXT2 may be a GlcA-transferase. To further 
study this, similar experiments as with the B16F10 mouse melanoma cells lacking EXT1, were 
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done using another cell line, a human melanoma MV3 cell line. This experiment was done only 
one time. 
 
 Protein expression analysis by Western blotting 
Full-length tGFP-EXT2 was transiently transfected into WT (WT+ EXT2) and EXT1KO (EXT1 
KO+EXT2) MV3 mouse melanoma cells using Lipofectamine. WT cells and EXT1KO cells 
treated with the transfection reagent (Lipofectamine) alone were used as controls, WT control and 
EXT1KO control, respectively.  The level of overexpression was analyzed by WB of cell lysates 
using an antibody to tGFP (Fig. 15A) and the expressed proteins quantified relative to GAPDH 
(Fig. 15B). Similar to transfection of tGFP-EXT2 into B16F10 EXT1KO cells, the protein 
expression levels in EXT1KO+EXT2 were lower than in WT+EXT2 cells. However, the difference 
in protein expression levels between EXT1KO+EXT2 and WT+EXT2 was not as large as in as in 
the experiment using mouse melanoma B16F10 cells (see Fig. 10B). 
 

































                
Fig. 15: Western blot analysis (A) and quantification of the expressed tGFP-EXT2 protein (B). (A) Cell extracts 
(35 µg cellular protein /lane) from EXT2 transfected cells and transfection reagent only treated control cells were 
separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (see “Methods”). The expressed 
proteins were detected with antibodies against tGFP (1:200) and GAPDH (1:2000) and visualized by 
chemiluminescence. The positions of molecular size standards (in kDa) are indicated. (B) The band intensity of 
detected proteins was quantified for one experiment by Imagej software and presented in the bar graphs as relative to 
GAPDH.  
A B 
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 EXT2 mRNA expression levels in WT control, EXT1KO control, WT+ EXT2 and EXT1 
KO+EXT2 MV3 human cells  
The relative amounts of EXT2 mRNA were determined by real-time PCR. RNA was extracted 
from the four different cell-types and cDNA was transcribed by reverse transcription and analyzed 
by PCR. The experiment was repeated two times. The expression levels of EXT2 in EXT1KO 
control cells was similar to like WT control cell, again showing that treatment with Lipofectamine 
did not affect endogenous levels of EXT2. Similar to the results from protein analysis and 
experiments using the B16F10 tGFPEXT2 transfected cells, EXT2 expression level was higher in 
WT transfected cells than in EXT1KO transfected cells (Fig. 16), again indicating that the 
transfection efficiency in EXT1KO cells was reduced compare to WT-cells.  
 



























































































































Fig. 16: mRNA levels of EXT2 protein in transfected and non-transfected MV3 human cells. Cells were 
transiently transfected with tGFP-tagged EXT2 (WT+ EXT2 and EXT1KO +EXT2) or treated with transfection 
reagent only (WT control and EXT1KO control) as described in “Experimental”. 24 hours after transfection relative 
mRNA levels were determined by real time PCR and normalized to those of A) POLR2F and B) S26. mRNA levels 
are expressed relative to the expression of the WT control that was set to 1. The error bars in A and B represent the 
mean from two analysis of a single transfection. Each measurement was performed in triplicate. 
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 Glycosyltransferase activity in WT control, EXT1KO control and EXT1 KO+EXT2 MV3 
human cells  
The catalytic properties of EXT2 protein were analyzed as in the experiments with B16F10 cells 
using two different in vitro transferase assays, both of which quantify the transfer of single sugars 
to acceptor molecules. In contrast to the experiment with B16F10 cells, the MV3 EXT1KO+EXT2 
did not show any transfer of GlcA or GlcNAc (Fig. 17). 
































    




























Fig. 17: GlcA-transferase and GlcNAc activities in EXT2 transfected and non-transfected MV3 cells. Crude cell-
lysates from cells, as indicated in the figures, were incubated with either radiolabeled UDP-GlcA or UDP-GlcNAc 
along with the unlabeled acceptor oligosaccharides and assayed for single sugar transfer to oligosaccharides with a 
nonreducing end A. GlcNAc (GlcA transferase activity) or B. GlcA (GlcNAc transferase activity). Labeled acceptor 
molecules elute in fractions 10-15. Material eluting after fraction 15 represent unincorporated labeled UDP-sugars. 
 
 EXT2 deficient B16F10 mouse melanoma transfected with full-length human 
C-terminal myc-DDK-tagged EXT1 plasmid DNA 
 
To study the enzyme activity of EXT1, cells lacking EXT2 were transfected with myc-DDK 
tagged EXT1 plasmid DNA and analyzed as in the experiments examining the enzyme activities 
of EXT2 using EXT1KO cells  
 Protein expression analysis by Western blotting.  
Full-length myc-DDK tagged EXT1 was transiently transfected into WT (WT+ EXT1) and 
EXT2KO (EXT2 KO+EXT1) B16F10 mouse melanoma cells using Lipofectamine. WT cells and 
EXT2KO cells treated with the transfection reagent (Lipofectamine) alone were used as controls, 
WT control and EXT2KO control, respectively.  The experiment was performed for single time 
and the level of overexpression analyzed by WB of cell lysates using an antibody to myc and 
A B 
37 | P a g e  
 
GAPDH (Fig. 18). myc-DDK tagged EXT1 has an apparent molecular weight of 87 kDa while the 
weight of GAPDH is 36 kDa.  
 
                  
 
Fig. 18: Western blot analysis. Cell extracts (50 µg cellular protein /lane) from EXT1 transfected cells and 
transfection reagent only treated control cells were separated by SDS-PAGE and transferred to a polyvinylidene 
difluoride membrane (see “Methods”). The expressed proteins were detected with antibodies against myc (1:500) and 
GAPDH (1:2000) and visualized by chemiluminescence. The positions of molecular size standards (in kDa) are 
indicated. Unspecific bands are observed in each lane. Arrow in 3rd lane indicates the myc tagged-EXT1 positive band 
in the WT+EXT1 sample.  
 
 EXT1 mRNA expression levels in WT control, EXT2KO control, WT+ EXT1 and 
EXT2KO+EXT1 B16F10 mouse melanoma cells.  
To determine the low amounts of expressed myc-DDK tagged EXT1 protein in WT+EXT1 cells 
and to analyze no transfected protein bands in EXT2KO+EXT1 cells, real-time PCR was 
performed. RNA was extracted from the four different cell-types and cDNA was transcribed by 
reverse transcription and analyzed by PCR. The experiment was done a single time. The expression 
level of EXT1 in EXT2KO+EXT1 cells was low, barely above the non-transfected EXT2KO 
control cells. The results from protein and mRNA analysis indicate poor transfection of 
EXT2KO+EXT1 cells (Fig.  19). 
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Fig. 19: mRNA level of EXT1 protein in transfected and non-transfected B16F10 mouse melanoma cells. Cells 
were transiently transfected with myc-DDK tagged EXT1 (WT+ EXT1 and EXT2KO +EXT1) or treated with 
transfection reagent only (WT control and EXT2KO control) as described in “Methods”. 24 hours after transfection 
relative mRNA levels were determined by real time PCR and normalized to those of A) Beta actin and B) S26. mRNA 
levels are expressed relative to the expression of the WT control that was set to 1. The bars in A and B represents real 
time PCR analysis of single transfection. Each measurement was performed in triplicate 
 Glycosyltransferase activity in WT control, EXT2KO control and EXT2 KO+EXT1 
B16F10 mouse melanoma cells  
The poor transfection results were also shown in the transferase assays (performed as described 
above). Transfected cells did not show any GlcA transferase activity and did not significant 
increase in GlcNAc transferase activity compared to EXT2KO control cells (Fig 20).  
 
                




























   
Fig. 20: GlcA-transferase and GlcNAc activities in EXT1 transfected and non-transfected B16F10 mouse 
melanoma cells. Crude cell-lysates from cells, as indicated in the figures, were incubated with either radiolabeled 
UDP-GlcA or UDP-GlcNAc along with the unlabeled acceptor oligosaccharides and assayed for single sugar transfer 
to oligosaccharides with a nonreducing end of A. GlcNAc (GlcA transferase activity) or B. GlcA (GlcNAc transferase 
activity). Labeled acceptor molecules elute in fractions 10-15. Material eluting around or after fraction 15 represent 
unincorporated labeled UDP-sugars. 
A B 
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7 DISCUSSION  
By interaction with a multitude of different molecules, HS plays important roles in many processes 
during development and in the adult organism. The signaling pathways of many growth factors 
(such as FGF) are dependent on the presence of HS. It is therefore important to understand HS 
biosynthesis in order to understand its functions. EXT1 and EXT2 protein have essential roles in 
HS biosynthesis. In vitro experiments have showed that EXT1 protein has detectable 
glycosyltransferase activity, but that function of EXT2 in HS biosynthesis is puzzling. The main 
objective of this project was to study the enzymatic activity of EXT2 and EXT1, focusing on EXT2.  
 
Expression and catalytic activities of EXT2 expressed in human and mouse EXT1KO cells 
EXT2 was transiently transfected into mouse melanoma B16F10 cells and human melanoma MV3 
cells lacking EXT1. As controls EXT2 was also transfected into corresponding WT cells. Western 
blot analysis and RT-PCR revealed rather poor transfection of EXT2 into EXT1KO cells as 
compared to the transfection of WT cells (Figs 10, 11, 15, 16). The reduced transfection efficiency 
was confirmed for B16F10 EXT1KO cells by staining of transfected cells using an antibody against 
the tGFP-tag (Fig. 14). The transfection reagent, Lipofectamine, forms cationic liposome-DNA 
complexes, that bind to negatively charged molecules on the cell membrane. Then the complexes 
fuse with the membrane and DNA is internalized into the cytoplasm (FELGNER et al., 1995). The 
reason for the poor transfection efficiency of KO cells lacking HS is most probably due to lack of 
the negatively charged cell surface HS chains that are necessary for the attachment of cationic 
liposomes (Mounkes et al., 1998)(Letoha et al., 2013).  
 
Transfection of EXT2 into mouse melanoma cells resulted in increased GlcA transferase activity 
(Fig. 12) but had no effect on GlcNAc transferase activity (Fig. 13). The EXT1KO cells had some 
but low GlcNAc transferase activity. This may be due to endogenous presence of EXTL3. EXTL3 
has been shown to have GlcNAc-transferase activity but no GlcA transferase activity  (Kim et al., 
2001). In contrast, transfection of EXT2 into the human melanoma EXT1KO cells did not increase 
GlcA (or GlcNAc) transferase activity (Fig. 17). There is no clear explanation for why transfection 
of the human melanoma MV3 cell line gave a different result than transfection of the mouse 
melanoma cell line. In both cell lines CRISPR/Cas9 was used to deplete EXT1 using the same the 
target-specific CRISPR guide RNA (Dr. Christian Gorzelanny, personal communication). One 
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explanation can be that too little protein was used in the transferase assays. Only 15µg cellular 
protein were used whereas approx. 30 µg cellular protein was used in transferase assays using 
mouse melanoma cells.  
 
In Kusche-Gullberg lab it has been verified that both the human and mouse KO cells completely 
lack HS chains. To confirm that the lack of HS in mouse EXT1KO and EXT2KO B16F10 cells 
were due to the deletion in EXT1 and EXT2 (caused by the CRISP-CAS9 treatment) an attempt 
was made to rescue these cells. To reintroduce EXT1 into EXT1KO cells and EXT2 into EXT2KO 
cells, the cells were transiently transfected with the myc-tagged EXT1 or tGFP-tagged EXT2, 
metabolically labeled with [3H]Glucosamine and the transfected cells analyzed for protein 
expression, mRNA expression  and [3H]labeled HS chains (data not shown). The transfection did 
not work, no tagged protein bands were detected by WB. Metabolic labeling of cells confirmed 
that the KO cells did not synthesize HS (data not shown).  
 
Expression and catalytic activities of EXT1 expressed in mouse EXT2KO cells 
Myc-tagged EXT1 was transiently transfected into mouse melanoma B16F10 cells lacking EXT2 
and, as a control, EXT1 was also transfected into WT B16F10 cells. The transfection efficiency 
was very low (Fig. 19) and only the transfected WT+EXT1 cells showed a weak band 
corresponding to the expressed myc-tagged EXT1 (Fig. 18). No GlcA transferase activity was 
observed in the EXT2KO control and EXT2KO+EXT1 cells. Some GlcNAc transferase activity 
was observed in both EXT1 transfected and KO control cells (Fig.  20). This may again be due to 
endogenous presence of EXTL3 in the cell lysates (Kim et al., 2001). It is difficult to draw any 
conclusion about the activity of EXT1 alone as the transfection appeared not to have worked. It is 
also possible that EXT1 protein cannot work properly in an EXT2 free background.  In a study by 
(Busse & Kusche-Gullberg, 2003) it was shown that co-expression of EXT1 with EXT2 resulted 
in increased GlcA transferase activity compared to the activity of EXT1 alone. This indicates that 
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What is the function of EXT2?  
Compared to EXT1, EXT2 has no clear glycosyltransferase activities but appears to have or at least 
promote GlcA transfer to the growing HS chain (Busse & Kusche-Gullberg, 2003). Clearly, EXT2 
influences and modulates the enzymatic activity of EXT1. Silencing using siRNA (approx. 85-90% 
downregulation of mRNA expression) of EXT2 has the same effect on the HS chain length as 
silencing of EXT1. It results in short HS chains (Busse et al., 2007). Also, mice lacking either 
EXT1 or EXT2 has the same phenotype, they die before gastrulation and lack HS chains (Lin et 
al., 2000) (Stickens et al., 2005). Overexpression of EXT1 results on longer HS chains whereas 
overexpression of EXT2 has no effect on HS chain length (Busse et al., 2007). EXT2 is needed for 
HS chain elongation, maybe as a part of a EXT1/EXT2 elongating complex or as a transfer protein 
necessary for the transfer of EXT1 from the ER to the Golgi apparatus (Busse & Kusche-Gullberg, 
2003) (McCormick et al., 2000)(Senay et al., 2000) 
 
Are the activities of EXT1 and EXT2 important for HS-protein interactions?  
One of the growth factors known to require HS for proper activation of its downstream signaling 
cascade, is FGF2. Fibroblasts with an EXT1 mutation that produce short HS chains with normal 
sulfation pattern show reduced proliferation rate, reduced FGF-2 signaling response and reduced 
ability to interact with collagen I (Österholm et al., 2009). These results show that the length of HS 
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8 CONCLUSION 
EXT1 and EXT2 have previously been demonstrated to form a complex, which has been suggested 
to be the HS elongating unit. The EXT1/EXT2 complex formation seems to be necessary for the 
translocation of these proteins from the endoplasmic reticulum to the Golgi apparatus. Moreover, 
the transferase activities of the EXT1/2 complex have been shown to be enhanced in comparison 
to the activities of the EXT1 and EXT2 alone. We found that EXT2 alone have enhanced GlcA-
transferase activity in the mouse melanoma cells but not in the human melanoma cells. The GlcA-
transferase activity of EXT2 cannot be explained by the presence of the EXTL-proteins. The 
EXTL-proteins have GlcNAc-transferase activity, but none of the EXTL-proteins have GlcA-
transferase activity.   
 
Several questions remain:  
1. Is EXT2 a glycosyltransferase or needed for re-localization of EXT1 to the Golgi 
apparatus?  
To answer this question the experiments using EXT1KO cells need to be repeated and the 
glycosyltransferase activity of EXT2 needs to be determined after purification of EXT2 by 
immunoprecipitation after expression in EXT1KO cells. 
2. How does the EXT1/2 complex form?  
Complex formation can be studied by expressing epitope-tagged EXT1 expression construct 
lacking the short cytosolic part, the transmembrane region, the stem region, or the catalytic luminal 
region expressed in B16-F10 EXT1KO cells. Complex formation with EXT2 can be studied using 
Western blotting and enzyme assays. 
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